Ro 23-9358 is a potent secretory phospholipase A2 inhibitor with anti-inflammatory activity.

LY433771 (LSN433771) (Compound 8) is a type X secretory phospholipase A2 (sPLA2) inhibitor with an IC50 value of 3 nM, which can be used in the study of cardiovascular diseases.

DPTIP hydrochloride is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC50 of 30 nM.

C10 Bisphosphonate is an inhibitor for acid sphingomyelinase. C10 Bisphosphonate is promising for research of inflammatory lung diseases, cystic fibrosis and atherosclerosis.

BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC50 of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of tau protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases.

ABC47 is a potent inhibitor of serine hydrolases. ABC47 shows IC50s of 0.03 and 0.1 μM for ABHD4 and ABHD3, respectively. ABC47 plays an important role in infantile neuronal ceroid lipofuscinosis research.

Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC50 of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction.

Pyrazole N-Desmethyl sildenafil (Compound 10) is an analog of Sildenafil.

PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD+), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer.

P7-2302 inhibits PDE7 and PDE4B with IC50 of 0.18 nM and 77.3 nM. P7-2302 inhibits the efflux of P-gp and BCRP (breast cancer resistance protein), exhibits low uptake in rats brain. P7-2302 can be used as a PET tracer when labeled with 18F.

MP 518 is a PDE inhibitor with antihypertensive properties. MP 518 can inhibit cAMP degradation, causing an increase in ICa, and can also antagonize β-adrenergic stimulation, exerting vasodilation.

Desmethyl thiosildenafil is a phosphodiesterase type 5 (PDE5) inhibitor[1].

Desethyl Sildenafil (Sildenafil impurity C) is the impurity of Sildenafil (IC50 of 134.29 μM).

Cipamfylline is a PDE4 inhibitor that can cause PDE4A4 to accumulate in specific areas of the cell through interaction with the ubiquitin scaffolding protein p62. Cipamfylline can be used in the research of atopic dermatitis.

BMS-341400 mesylate (Compound 6) is an orally active and a selective phosphodiesterase 5 (PDE5) inhibitor, with IC50 of 0.3 nM. BMS-341400 mesylate can be used for research of erectile dysfunction.

BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.

ASP9831 is an orally active PDE4 inhibitor. ASP9831 inhibits LSP-induced TNF-α production and has anti-inflammatory activity. ASP9831 can be used in fatty liver disease research.

4-Nitrophenyl phenylphosphonate is a substrate for 5'-nucleotide phosphodiesterase.

(±)-BAY-7081 is a racemate of BAY-7081.

(+)-BAY-7081 is an optical isomer of BAY-7081.

SDUY817 is a dual APN/NEP inhibitor, with IC50 values of 0.29 μM for APN and 7.4 μM for NEP. SDUY817 exerts analgesic effects in a concentration- and time-dependent manner, and can be used for research in the field of neuropathic pain disorders.

WY-50295 is an orally active and selective 5-lipoxygenase inhibitor. WY-5029 inhibits LTB4 formation in rat whole blood leukocytes (IC50: 40 μM and oral ED50: 18 mg/kg). WY-50295 can be used in the study of asthma and other leukotriene-dependent diseases.

NCTT-956 is a very effective platelet 12-lipoxygenase (12-LOX) activity-specific inhibitor.

BLX-3887 is a selective 15-lipoxygenase type 1 (15-LO-1) inhibitor with an IC50 of 32 nM. BLX-3887 can be utilized in research related to the 15-LO pathways.

15(S)-HEDE (Compound 8) is an analogue of 15-HEDE-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models.

Lanisidenib is the inhibitor for isocitrate dehydrogenase that exhibits antineoplastic activity.

Crelosidenib (gentisate) is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50 of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Crelosidenib (gentisate) is less active at inhibiting the IDH wild-type enzymes.

XW-032 is an apo-IDO1 inhibitor, with an IC50 of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer.

L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. L-645164 produces substantial decreases in circulating serum cholesterol concentrations in dogs. L-645164 is promising for research of central nervous system disorders.

4-Hydroxy atorvastatin hemicalcium is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin.